June M Tordoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/273470/publications.pdf

Version: 2024-02-01

67 1,276 18 33 g-index
68 68 68 1635

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	A systematic review and metaâ€analysis of pharmacistâ€led feeâ€forâ€services medication review. British Journal of Clinical Pharmacology, 2014, 77, 102-115.	2.4	148
2	Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS ONE, 2016, 11, e0151066.	2.5	148
3	Continuation of Proton Pump Inhibitors from Hospital to Community. International Journal of Clinical Pharmacy, 2006, 28, 189-193.	1.4	68
4	Medicine-taking practices in community-dwelling people aged >=75 years in New Zealand. Age and Ageing, 2010, 39, 574-580.	1.6	60
5	General practitioners' perceptions of pharmacists' new services in New Zealand. International Journal of Clinical Pharmacy, 2012, 34, 364-373.	2.1	51
6	General practitioners' insight into deprescribing for the multimorbid older individual: a qualitative study. International Journal of Clinical Practice, 2016, 70, 261-276.	1.7	48
7	Potentially inappropriate medicines in a cohort of communityâ€dwelling older people in <scp>N</scp> ew <scp>Z</scp> ealand. Geriatrics and Gerontology International, 2014, 14, 89-93.	1.5	47
8	â€~What do patients want?' Tailoring medicines information to meet patients' needs. Research in Social and Administrative Pharmacy, 2017, 13, 1186-1190.	3.0	47
9	"lt's just routine.―A qualitative study of medicine-taking amongst older people in New Zealand. International Journal of Clinical Pharmacy, 2010, 32, 154-161.	1.4	46
10	Effect of the Pediatric Exclusivity Provision on children's access to medicines. British Journal of Clinical Pharmacology, 2005, 59, 730-735.	2.4	34
11	Non-medical prescribing in New Zealand: an overview of prescribing rights, service delivery models and training. Therapeutic Advances in Drug Safety, 2017, 8, 349-360.	2.4	30
12	Older people's experiences of medicine changes on leaving hospital. Research in Social and Administrative Pharmacy, 2014, 10, 791-800.	3.0	28
13	Examining the first year of Medicines Use Review services provided by pharmacists in New Zealand: 2008. New Zealand Medical Journal, 2009, 122, 3566.	0.5	27
14	A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics, 2012, 30, 1051-1065.	3.3	26
15	The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand. Value in Health, 2010, 13, 148-156.	0.3	23
16	Impact of prescription charges on people living in poverty: A qualitative study. Research in Social and Administrative Pharmacy, 2016, 12, 893-902.	3.0	23
17	Trends in accessibility to medicines for children in New Zealand: 1998-2002. British Journal of Clinical Pharmacology, 2003, 57, 322-327.	2.4	22
18	SimPharm: How pharmacy students made meaning of a clinical case differently in paper―and simulationâ€based workshops. British Journal of Educational Technology, 2011, 42, 865-874.	6.3	22

#	Article	IF	CITATIONS
19	Psychotropic Medicine Utilization in Older People in New Zealand from 2005 to 2013. Drugs and Aging, 2014, 31, 755-768.	2.7	21
20	Changes in availability of paediatric medicines in Australia between 1998 and 2002. British Journal of Clinical Pharmacology, 2005, 59, 736-742.	2.4	20
21	Pediatric Licensing Status and the Availability of Suitable Formulations for New Medical Entities Approved in the United States Between 1998 and 2002. Journal of Clinical Pharmacology, 2006, 46, 1038-1043.	2.0	20
22	"Price Management―and Its Impact on Hospital Pharmaceutical Expenditure and the Availability of Medicines in New Zealand Hospitals. Value in Health, 2008, 11, 1214-1226.	0.3	17
23	Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand. International Journal of Clinical Pharmacy, 2014, 36, 503-512.	2.1	17
24	Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998?2002. British Journal of Clinical Pharmacology, 2007, 63, 85-91.	2.4	16
25	Pharmacists' performance of clinical interventions during adherence support medication reviews. Research in Social and Administrative Pharmacy, 2014, 10, 185-194.	3.0	16
26	Temporal trends in the utilisation of preventive medicines by older people: A 9-year population-based study. Archives of Gerontology and Geriatrics, 2016, 62, 103-111.	3.0	14
27	Regulatory agencies' recommendations for medicine information leaflets: Are they in line with research findings?. Research in Social and Administrative Pharmacy, 2018, 14, 196-202.	3.0	14
28	Access to prescribing information for paediatric medicines in the USA: postâ€modernization. British Journal of Clinical Pharmacology, 2009, 67, 341-346.	2.4	12
29	Do Residents Need All Their Medications? A Cross-Sectional Survey of RNs' Views on Deprescribing and the Role of Clinical Pharmacists. Journal of Gerontological Nursing, 2017, 43, 13-20.	0.6	12
30	Managing Prices for Hospital Pharmaceuticals: A Successful Strategy for New Zealand?. Value in Health, 2005, 8, 201-208.	0.3	11
31	Documenting pharmacist's clinical interventions in New Zealand hospitals. International Journal of Clinical Pharmacy, 2007, 30, 99-106.	1.4	11
32	<p>Exploring Medicines Burden Among Adults in New Zealand: A Cross-Sectional Survey</p> . Patient Preference and Adherence, 2019, Volume 13, 2171-2184.	1.8	11
33	Use of centrally developed pharmacoeconomic assessments for local formulary decisions. American Journal of Health-System Pharmacy, 2006, 63, 1613-1618.	1.0	10
34	Examining potentially inappropriate prescribing in residential care using the STOPP/START criteria. European Geriatric Medicine, 2016, 7, 40-46.	2.8	10
35	Using an Electronic Decision Support Tool to Reduce Inappropriate Polypharmacy and Optimize Medicines: Rationale and Methods. JMIR Research Protocols, 2016, 5, e105.	1.0	10
36	Older people's attitudes towards their regular medicines. Journal of Primary Health Care, 2013, 5, 234-42.	0.6	10

#	Article	IF	CITATIONS
37	Community pharmacists' perceptions of services that benefit older people in New Zealand. International Journal of Clinical Pharmacy, 2012, 34, 342-350.	2.1	9
38	General practitioners' views of pharmacists' current and potential contributions to medication review and prescribing in New Zealand. Journal of Primary Health Care, 2013, 5, 223-33.	0.6	9
39	An international validation study of two achievement goal measures in a pharmacy education context. Advances in Medical Education and Practice, 2014, 5, 339.	1.5	8
40	KEY INFORMANTS' PERCEPTIONS OF HOW PHARMAC OPERATES IN NEW ZEALAND. International Journal of Technology Assessment in Health Care, 2012, 28, 367-373.	0.5	7
41	An International Comparison Study of Pharmacy Students' Achievement Goals and their Relationship to Assessment Type and Scores. American Journal of Pharmaceutical Education, 2015, 79, 35.	2.1	7
42	Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand. International Journal of Clinical Pharmacy, 2016, 38, 941-949.	2.1	7
43	Patient-focused medicines information: General practitioners' and pharmacists' views on websites and leaflets. Health Education Journal, 2019, 78, 340-351.	1.2	7
44	Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007. International Journal of Clinical Pharmacy, 2010, 32, 386-393.	1.4	6
45	Do health professionals tell patients what they want to know about their medicines?. Health Education Journal, 2018, 77, 762-777.	1.2	6
46	New Zealand Health Care Editorial $\hat{A}-$ Prescription Charges: Prescription charge increase in new Zealand penalise the poor and sick. Journal of Primary Health Care, 2014, 6, 4.	0.6	6
47	Older people's perceptions of prescription medicine costs and related costs: a pilot study in New Zealand. Journal of Primary Health Care, 2014, 6, 295.	0.6	5
48	Patients' views of general practitioners' provision of medicine information leaflets. Journal of Primary Health Care, 2019, 11, 359.	0.6	5
49	One of us: Stories from two New Zealand rest homes. Journal of Aging Studies, 2015, 35, 135-143.	1.4	4
50	Quality in residential care: exploring residents', family members', managers' and staff perspectives. Quality in Ageing and Older Adults, 2016, 17, 253-262.	0.8	4
51	ldentifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment. Applied Health Economics and Health Policy, 2021, 19, 253-266.	2.1	4
52	Quality Use of Medicines activities in New Zealand hospitals from 2000 to 2002. New Zealand Medical Journal, 2005, 118, U1259.	0.5	4
53	Processes for the Assessment and Introduction of New Medicines in New Zealand Hospitals. Journal of Pharmacy Practice and Research, 2004, 34, 267-271.	0.8	3
54	Health Professionals: How Do They Assess New Medicines?. International Journal of Clinical Pharmacy, 2005, 27, 236-242.	1.4	3

#	Article	IF	CITATIONS
55	Geographic variation in psychotropic drug utilisation among older people in <scp>N</scp> ew <scp>Z</scp> ealand. Australasian Journal on Ageing, 2016, 35, 242-248.	0.9	3
56	Doctors and pharmacists provision and opinions of medicines information leaflets in New Zealand. International Journal of Clinical Pharmacy, 2018, 40, 676-685.	2.1	3
57	Examining non-medical prescribing trends in New Zealand: 2016–2020. BMC Health Services Research, 2021, 21, 418.	2.2	3
58	Identifying New Zealand Public Preferences for Pharmacist Prescribers in Primary Care: A Discrete Choice Experiment. Patient, 2022, 15, 77-92.	2.7	3
59	Quality use of antipsychotic medicines inresidential aged care facilities in New Zealand. Journal of Primary Health Care, 2016, 8, 335.	0.6	2
60	Older people's perceptions of prescription medicine costs and related costs: a pilot study in New Zealand. Journal of Primary Health Care, 2014, 6, 295-303.	0.6	2
61	Influence of the National Hospital Pharmaceutical Strategy on the Assessment of New Medicines in New Zealand Public Hospitals. Journal of Pharmacy Practice and Research, 2005, 35, 271-275.	0.8	1
62	Workforce and Service Delivery Analysis across New Zealand Hospital Pharmacy Departments. Journal of Pharmacy Practice and Research, 2006, 36, 271-274.	0.8	1
63	Pharmacoeconomics: a Reliable Tool for Decisions on New Medicines?. Journal of Pharmacy Practice and Research, 2006, 36, 12-15.	0.8	1
64	The Authors' Reply to Wonder and Milne: "Comparing Subsidized Access to Medicines Across Payer Systems― Pharmacoeconomics, 2013, 31, 175-176.	3.3	1
65	The influence of PHARMAC's National Hospital Pharmaceutical Strategy on Quality Use of Medicines activities in New Zealand hospitals. New Zealand Medical Journal, 2006, 119, U2100.	0.5	1
66	Prescription charge increases in New Zealand penalise the poor and sick. Journal of Primary Health Care, 2014, 6, 4-5.	0.6	1
67	Poverty, medicines and health care: It's the little things…. Journal of Primary Health Care, 2015, 7, 170-1.	0.6	0